Selective estrogen receptor modulators (SERMs) exhibit a pharmacologic profile characterized by estrogen agonist activity in some tissues with estrogen antagonist activity in other tissues. These compounds were initially called “antiestrogens,” but it was subsequently recognized that this inadequately described their spectrum of activities. The first widely used SERM, tamoxifen, has estrogen antagonist activity in breast tissue but shows estrogen-like activity in other tissues. Raloxifene is another SERM in clinical use, and it was developed to avoid some of the undesirable estrogen agonist actions of other SERMs to improve the drug safety profile. Raloxifene has been introduced for clinical use in treatment and prevention of postmenopausal osteoporosis.
This study directly compares Raloxifene’s effectiveness in reversing gyno to Nolvadex.
It was determined that “inhibition of estrogen receptor action in the breast appears to be safe and effective in reducing persistent pubertal gynecomastia, with a better response to raloxifene than to tamoxifen.”
Dosages are followed identically if used in place of Nolvadex. However if used in a gyno reversal protocol we suggest the following :
Raloxifene 60 mg/day for 10 days, then 30mg/day until gyno is reversed.
Supplementing 5000 IU Vitamin D daily, and 500 mg of Calcium daily.